Semaglutide reduces major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease and overweight or obesity without diabetes
Current assessment
Synthesis pending
Confidence
Not assessed
Supporting evidence (0)
Nothing recorded on this side
Contradicting evidence (0)
Nothing recorded on this side
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.